US › Healthcare

Verrica Pharmaceuticals Inc (VRCA)

US · Healthcare · Biotechnology

$5.41+3.05%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$5.0M
Revenue YoY
+46.1%
Net profit
$-9.7M
Profit YoY
+0.6%
EPS
$-0.45
EPS estimate
$-0.59
Net margin
-192.8%

EPS came in at -0.45 against a street estimate of -0.59 — a beat of 23.0%.

Key statistics

Market cap
$89.7M
Forward P/E
0.0
P/B
5.57
Book value
$0.94
EPS (TTM)
$-1.10
52-week high
$9.82
52-week low
$3.28
50-day MA
$5.86
200-day MA
$6.09
Beta
1.48

Analyst view

Analysts rate Verrica Pharmaceuticals Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $15.54.

Shareholding

Insiders
48.75%
Institutions
27.87%

Largest institutional holders

FundStake
Caligan Partners LP5.38%
Affinity Asset Advisors, LLC4.12%
Cannell Capital LLC3.99%
Armistice Capital, LLC3.02%
Velan Capital Investment Management LP2.75%
BOOTHBAY FUND MANAGEMENT, LLC1.63%
Vanguard Capital Management, LLC1.10%
Dafna Capital Management LLC0.89%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Verrica Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.